Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Intellia Therapeutics Inc buy Guggenheim

Intellia Therapeutics Inc
Start price
€7.88
12.05.25 / 50%
Target price
€40.09
12.05.26
Performance (%)
50.25%
End price
€11.84
13.05.26
Summary
This prediction ended on 13.05.26 with a price of €11.84. The BUY prediction by Guggenheim for Intellia Therapeutics Inc saw massive gains of 50.25%. Guggenheim has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Intellia Therapeutics Inc 10.643% 10.643% 12.830%
iShares Core DAX® 0,63 % 4,95 % 8,66 %
iShares Nasdaq 100 1,16 % -1,16 % 26,82 %
iShares Nikkei 225® 2,36 % -1,35 % 48,19 %
iShares S&P 500 0,63 % 1,38 % 22,99 %

Comments by Guggenheim for this prediction

In the thread Intellia Therapeutics Inc diskutieren
Prediction Buy
Perf. (%) 50.25%
Target price 40.086
Change
Ends at 12.05.26

Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Guggenheim from $55.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat

Guggenheim 
0
Report Share
12.05.25
In the thread Trading Intellia Therapeutics Inc
Prediction Buy
Perf. (%) 50.25%
Target price 40.086
Change
Ends at 12.05.26

Die von Guggenheim gewählte maximale Laufzeit wurde überschritten

Guggenheim 
0
Report Share
13.05.26